



WHAT IS CLAIMED IS:


1. A compound represented by Formula (I) or (II):




or



or a pharmaceutically acceptable salt thereof, wherein
HET-1 is one of the following heterocycles:




HET-2 is one of the following heterocycles:



R¹ is:

- (a) H;
- 5 (b) C₁-C₆-alkyl, C₂-C₄-alkenyl, C₂-C₄-alkynyl, C₁-C₆-cycloalkyl, or C₁-C₄-alkyl-[C₁-C₆-cycloalkyl], any of which is optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, S(O)₀₋₂-(C₁-C₄)alkyl, O-CONR^aR^b, NR^aR^b, N(R^a)CONR^aR^b, COO-(C₁-C₄)alkyl, COOH, CN, CONR^aR^b, SO₂NR^aR^b, N(R^a)SO₂NR^aR^b, -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
- 10 (c) -O-C₁-C₆-alkyl, -O-C₁-C₆-cycloalkyl, -S-C₁-C₆-alkyl or -S-C₁-C₆-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, S(O)₀₋₂-(C₁-C₄)alkyl, O-CONR^aR^b, NR^aR^b, N(R^a)CONR^aR^b, COO-(C₁-C₄)alkyl, COOH, CN, CONR^aR^b, SO₂NR^aR^b, N(R^a)SO₂NR^aR^b, -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
- 15 (d) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl, or -O-C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl;
- (e) -OH;
- 20 (f) -O-aryl, or -O-C₁-C₄-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁-10alkyl, and xiv) -C₁-10alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;
- 25

- (g) $-OCON(R^a)(R^b)$, or $-OSO_2N(R^a)(R^b)$;
 (h) $-SH$, or $-SCON(R^a)(R^b)$;
 (i) NO_2 ;
 (j) NR^aR^b , $-N(COR^a)R^b$, $-N(SO_2R^a)R^b$, $-N(R^a)CON(R^a)_2$, $-N(R^a)CONH_2$, $-N(OR^a)CONR^aR^b$,
 5 $N(R^a)CON(R^a)_2$, or $-N(R^a)SO_2N(R^a)_2$;
 (k) $-CH(OR^a)R^a$, $-C(OR^b)CF_3$, $-CH(NHR^b)R^a$, $-C(=O)R^a$, $C(=O)CF_3$, $-SOCH_3$, $-SO_2CH_3$,
 $N(R^a)SO_2R^a$, $COOR^a$, CN , $CONR^aR^b$, $-COCONR^aR^b$, $-SO_2NR^aR^b$, $-CH_2O-SO_2NR^aR^b$,
 $SO_2N(R^a)OR^a$, $-C(=NH)NH_2$, $-CR^a=N-OR^a$, $CH=CHCONR^aR^b$, $CONR^a$, $CONHR^a$;
 (l) $-CONR^a(CH_2)_{0-2}C(R^a)(R^b)(CH_2)_{0-2}CONR^aR^b$;
 10 (m) tetrazolyl, tetrazolinonyl, triazolyl, triazolinonyl, imidazolyl, imidozolonyl, oxazolyl,
 oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrazolonyl, pyrrolyl, pyridyl,
 pyrimidinyl, pyrazinyl, or phenyl, any of which is optionally substituted with 1-3 independent
 substituents selected from i) F, Cl, Br, I, ii) $-CN$, iii) $-NO_2$, iv) $-C(=O)R^a$, v) C_1-C_6 -alkyl, vi)
 $-OR^a$, vii) $-NR^aR^b$, viii) $-C_0-C_4$ -alkyl $-CO-OR^a$, ix) $-(C_0-C_4$ -alkyl)- $NH-CO-OR^a$, x) $-(C_0-C_4$ -
 15 alkyl)- $CO-NR^aR^b$, xi) $-S(O)_{0-2}R^a$, xii) $-SO_2NR^aR^b$, xiii) $-NH-SO_2R^a$, xiv) $-C_1-C_4$ -
 perfluoroalkyl, and xv) $-O-C_1-C_4$ -perfluoroalkyl;
 (n) $-C(R^a)=C(R^b)-COOR^a$, or $-C(R^a)=C(R^b)-CONR^aR^b$;
 (o) piperidin-1-yl, morpholin-4-yl, pyrrolidin-1-yl, piperazin-1-yl or 4-substituted piperazin-1-
 yl, any of which is optionally substituted with 1-3 substituents selected from i) $-CN$, ii) -



- 20 $C(=O)(R^a)$, iii) C_1-C_6 -alkyl, iv) $-OR^a$, v) $-NR^aR^b$, vi) $-C_0-C_4$ -alkyl $-CO-OR^a$, vii) $-(C_0-C_4$ -alkyl)-
 $NH-CO-OR^a$, viii) $-(C_0-C_4$ -alkyl)- $CON(R^a)(R^b)$, ix) $-SR^a$, x) $-S(O)_{0-2}R^a$, xi) $-SO_2N(R^a)(R^b)$, xii)
 $-NR^aSO_2R^a$, xiii) $-C_1-C_4$ -perfluoroalkyl and xiv) $-O-C_1-C_4$ -perfluoroalkyl;

R^a is

- (a) H;
 25 (b) C_1-C_4 -alkyl, optionally substituted with one or more of the following substituents: F, CF_3 ,
 OH, $O-(C_1-C_4)$ -alkyl, $S(O)_{0-2}-(C_1-C_4)$ -alkyl, $-OCONH_2$, $-OCONH(C_1-C_4$ -alkyl), $-OCON(C_1$ -
 C_4 -alkyl)(C_1-C_4 -alkyl), $-OCONH(C_1-C_4$ -alkyl-aryl), $-OCON(C_1-C_4$ -alkyl)(C_1-C_4 -alkyl-aryl), NH_2 ,
 $NH(C_1-C_4$ -alkyl), $N(C_1-C_4$ -alkyl)(C_1-C_4 -alkyl), $NH(C_1-C_4$ -alkyl-aryl), $N(C_1-C_4$ -alkyl)(C_1-C_4 -alkyl-
 aryl), $NHCONH_2$, $NHCONH(C_1-C_4$ -alkyl), $NHCONH(C_1-C_4$ -alkyl-aryl), $-NHCON(C_1$ -
 30 C_4 -alkyl)(C_1-C_4 -alkyl), $NHCON(C_1-C_4$ -alkyl)(C_1-C_4 -alkyl-aryl), $N(C_1-C_4$ -alkyl)CON(C_1 -
 C_4 -alkyl)(C_1-C_4 -alkyl), $N(C_1-C_4$ -alkyl)CON(C_1-C_4 -alkyl)(C_1-C_4 -alkyl-aryl), $COO-(C_1-C_4$ -alkyl),

- COOH, CN, CONH₂, CONH(C₁-C₄alkyl), CON(C₁-C₄alkyl)(C₁-C₄alkyl), SO₂NH₂, SO₂NH(C₁-C₄alkyl), SO₂NH(C₁-C₄alkyl-aryl), SO₂N(C₁-C₄alkyl)(C₁-C₄alkyl), NHSO₂NH₂, -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
- 5 (c) C₀-C₄-alkyl-(C₁-C₄)-perfluoroalkyl; or
- (d) C₁-C₄-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(C₁-C₄-alkyl), v) -O(C₁-C₄-alkyl), vi) -N(C₁-C₄-alkyl)(C₁-C₄-alkyl), vii) -C₁-10alkyl, and viii) -C₁-10alkyl, wherein one or more of the alkyl carbons can be replaced by a -, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;
- 10 R^b is
- 15 (a) H; or
- (b) C₁-C₆-alkyl, optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, S(O)₀₋₂-(C₁-C₄)alkyl, -OCONH₂, -OCONH(C₁-C₄alkyl), NH₂, NH, NH(C₁-C₄alkyl), N(C₁-C₄alkyl), N(C₁-C₄alkyl)(C₁-C₄alkyl), NHCONH₂, NHCONH(C₁-C₄alkyl), -NHCON(C₁-C₄alkyl)(C₁-C₄alkyl), COO-(C₁-C₄-alkyl), COOH, CN, pyridyl, piperidinyl, pyrimidinyl, piperazinyl, CONH₂ or (C₁-C₄alkyl)CONH₂; or
- 20 R^a and R^b, together with the N to which they are attached, can form a 5- or 6-membered ring which optionally contains a heteroatom selected from N, O, and S, and wherein said ring is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁-10alkyl, and xiv) -O-;
- 25

R² and R³ each independently is:

- (a) H;
- 30 (b) -C₁-C₄-alkyl, or -O-C₁-C₄-alkyl;
- (c) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl, or -O-C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl; or
- (d) CN, N R^a R^b, NO₂, F, Cl, Br, I, OH, OCONR^a R^b, O(C₁-C₄-alkyl)CONR^a R^b, -OSO₂NR^a R^b, COOR^a, or CONR^a R^b;

R⁴ and R⁵ each independently is:

- (a) H;
 - (b) -C₁-C₆-alkyl, -C₂-C₆-alkenyl, -C₂-C₆-alkynyl or -C₁-C₆-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF₃, -O-(C₁-C₄)alkyl, CN, -N(R^a)(R^b), -N(R^a)CO-(C₁-C₄)alkyl, COOR^b, CON(R^a)(R^b) and phenyl;
 - (c) -O-C₀-C₆-alkyl, -O-aryl, or -O-C₁-C₄-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀-4alkyl-CO-OR^a, viii) -(C₀-4alkyl)-NH-CO-OR^a, ix) -(C₀-4alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁-10alkyl, and xiv) -C₁-10alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;
 - (d) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl, or -O-C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl; or
 - (e) CN, NH₂, NO₂, F, Cl, Br, I, OH, OCON(R^a)(R^b) O(C₁-C₄-alkyl)CONR^aR^b, -OSO₂N(R^a)(R^b), COOR^b, CON(R^a)(R^b), or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀-4alkyl-CO-OR^a, viii) -(C₀-4alkyl)-NH-CO-OR^a, ix) -(C₀-4alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁-10alkyl, and xiv) -C₁-10alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-; and
- 25 R⁶, R⁷ and R⁸ each independently is:
- (a) H;
 - (b) C₁-C₆-alkyl, C₂-C₄-alkenyl, C₂-C₄-alkynyl or C₁-C₆-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, OCON(R^a)(R^b), NR^aR^b, COOR^a, CN, CONR^aR^b, N(R^a)CONR^aR^b, N(R^a)SO₂NR^aR^b, SO₂NR^aR^b, S(O)₀₋₂(C₁-C₄-alkyl), -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, and piperazinyl;
 - (c) -O-C₁-C₆-alkyl, -O-C₁-C₆-cycloalkyl, -S-C₁-C₆-alkyl or -S-C₁-C₆-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-


- C₄)alkyl, NH₂, NH(C₁-C₄-alkyl), N(C₁-C₄-alkyl)₂, COOH, CN, CONH₂, CONH(C₁-C₄-alkyl), CONH(C₁-C₄-alkyl)₂, SO₂NH₂, SO₂NH(C₁-C₄-alkyl), tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;
- 5 (d) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl, or -O-C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl;
- (e) -O-aryl, or -O-C₁-C₄-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-; or
- 10 (f) CN, N(R^a)(R^b), NO₂, F, Cl, Br, I, -OR^a, -SR^a, -OCON(R^a)(R^b), -OSO₂N(R^a)(R^b), COOR^b, CON(R^a)(R^b), -N(R^a)CON(R^a)(R^b), -N(R^a)SO₂N(R^a)(R^b), -C(OR^b)R^a, -C(OR^a)CF₃, -C(NHR^a)CF₃, -C(=O)R^a, C(=O)CF₃, -SOCH₃, -SO₂CH₃, -NHSO₂(C₁₋₆-alkyl), -NHSO₂-aryl, SO₂N(R^a)(R^b), -CH₂OSO₂N(R^a)(R^b), SO₂N(R^b)-OR^a, -C(=NH)NH₂, -CR_a=N-OR_a, CH=CH or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;
- 20 or -C≡C-; or when R⁶ and R⁷ are present on adjacent carbon atoms, R⁶ and R⁷, together with the benzene ring to which they are attached, can form a bicyclic aromatic ring selected from naphthyl, indolyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzofuryl, benzothienyl, benzoxazolyl, benzothiazolyl, and benzimidazolyl, any of which is optionally substituted with 1-4 independent substituents selected from i) halogen, ii) -CN, iii) -NO₂, iv) -CHO, v) -O-C₁₋₄alkyl, vi) -N(C₀₋₄alkyl)(C₀₋₄alkyl), vii) -C₀₋₄alkyl-CO-O(C₀₋₄alkyl), viii) -(C₀₋₄alkyl)-NH-CO-O(C₀₋₄alkyl), ix) -(C₀₋₄alkyl)-CO-N(C₀₋₄alkyl)(C₀₋₄alkyl), x) -S(C₀₋₄alkyl), xi) -S(O)(C₁₋₄alkyl), xii) -SO₂(C₀₋₄alkyl), xiii) -SO₂N(C₀₋₄alkyl)(C₀₋₄alkyl), xiv) -NHSO₂(C₀₋₄alkyl)(C₀₋₄alkyl), xv) -C₁₋₁₀alkyl and xvi) -C₁₋₁₀alkyl in which one or more of the carbons
- 30

can be replaced by a -N(C₀-6alkyl)-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(C₀-6alkyl)-, -N(C₀-6alkyl)-C(O)-, -N(C₀-6alkyl)-C(O)-N(C₀-6alkyl)-, -C(O)-, -CH(OH), -C=C-, or -C≡C-.

2. The compound according to Claim 1 represented by Formula (I), or a
5 pharmaceutically acceptable salt thereof.


3. The compound according to Claim 2, or a pharmaceutically acceptable salt
thereof, wherein

10 HET-1 is




4. The compound according to Claim 2, or a pharmaceutically acceptable salt
thereof, wherein

15 HET-1 is




5. The compound according to Claim 2, or a pharmaceutically acceptable salt
20 thereof, wherein

HET-1 is




- 5 6. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is




- 10 7. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is




- 15 8. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



9. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



10. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is




11. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

R6 is other than H and is attached at the ortho position.

12. The compound according to Claim 1 represented by Formula (II), or a pharmaceutically acceptable salt thereof.


13. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is




14. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

5 HET-2 is




15. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is




16. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is




17. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is




- 5 18. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is




- 10 19. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is




- 15 20. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



- 5 21. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein


HET-1 is



and


10

HET-2 is



- 15 22. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein


HET-1 is



and


20

HET-2 is




23. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is




and

HET-2 is




24. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



25. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein


HET-1 is



5

26. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein


HET-1 is



10

27. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein


HET-1 is



15

28. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is




20

25


29. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

5 HET-1 is




10 30. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is





15 31. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein




















20 HET-1 is



32. A compound represented by











or a pharmaceutically acceptable salt thereof.

33. A compound represented by


5



or a pharmaceutically acceptable salt thereof.




34. The compound of Claim 1 represented by

5









R ⁶	R ⁷	R ²	R ¹
OCF ₃	H	H	H
OCF ₃	H	H	
OCF ₃	H	H	-SCH ₃
OCF ₃	H	H	-SO ₂ CH ₃
OCF ₃	H	H	-SOCH ₃
OCF ₃	H	H	NH ₂
OCF ₃	H	H	NHSO ₂ CH ₃
OCF ₃	H	H	N(SO ₂ CH ₃) ₂
OCF ₃	H	H	NHCO(CH ₃) ₃
OCF ₃	H	H	CON(CH ₃)OCH ₃
OCF ₃	H	H	
OCF ₃	H	H	CH ₃ CO
OCF ₃	H	H	CONHC(CH ₃) ₂ COOCH ₃
OCF ₃	H	H	CONHCH ₂ CH ₂ CN
OCF ₃	H	H	CONHC(CH ₃) ₂ COOH
OCF ₃	H	H	CONHC(CH ₃) ₂ CONH ₂
OCF ₃	H	H	CON(CH ₂ CH ₂) ₂ NH
OCF ₃	H	H	
OCF ₃	H	H	CONHC(CH ₂) ₂ COOCH ₃





R ⁶	R ⁷	R ²	R ¹
OCF ₃	H	H	CONHC(CH ₂) ₂ COOH
OCF ₃	H	H	CONHC(CH ₂) ₂ CONH ₂
OCF ₃	H	H	CON(CH ₂) ₂ N(CH ₃) ₂
OCF ₃	H	H	CONHCH ₃
OCF ₃	H	H	CON(CH ₃) ₂
OCF ₃	H	H	COOCH ₃
OCF ₃	H	H	CONHCH(CH ₃)CONH ₂ (S)
OCF ₃	H	H	CON(CH ₂) ₂ 
OCF ₃	H	H	CONHC(CH ₃) ₃
OCF ₃	H	H	CON(CH ₃) ₂ CH ₂ OH
OCF ₃	H	H	CONHCH(CH ₃)CONH ₂ (R)
OCF ₃	H	H	
OCF ₃	H	CH ₃	CH ₃
OCF ₃	H	CH ₃	COOH
OCF ₃	H	CH ₃	CONH ₂
OCF ₃	H	H	CONHCH ₂ CONH ₂
OCF ₃	H	Cl	CH ₃
OCF ₃	H	Cl	CONH ₂
OCF ₃	H	H	NHCONH ₂
CF ₃	H	H	CH ₃
CF ₃	H	H	H

R ⁶	R ⁷	R ²	R ¹
CF ₃	H	H	COOH
CF ₃	H	H	CONH ₂
CF ₃	H	H	
CF ₃	H	H	SH
CF ₃	H	H	S-COCH ₃
CF ₃	H	H	Cl
CF ₃	H	H	CN
CF ₃	H	H	
CF ₃	5-F	H	CH ₃
CF ₃	5-F	H	COOH
CF ₃	5-F	H	CONH ₂
CF ₃	4-F	H	CONH ₂
CF ₃	4-Cl	H	CONH ₂
Cl	6-Cl	H	CONH ₂
CF ₃	6-CF ₃	H	COOH
CF ₃	6-CF ₃	H	CONH ₂
CF ₃	4-CF ₃	H	CH ₃
CF ₃	4-CF ₃	H	COOH
CF ₃	4-CF ₃	H	CONH ₂
CF ₃	4-CF ₃	H	

R ⁶	R ⁷	R ²	R ¹
O-Ph	H	H	CH ₃
O-Ph	H	H	COOH
O-Ph	H	H	CONH ₂
H	O-Ph	H	CONH ₂
Cl	H	H	CH ₃
H	3-Cl	H	CH ₃
-SO ₂ NH-tBu	H	H	CH ₃
-SO ₂ NH ₂	H	H	CH ₃
-CONH-tBu	H	H	CH ₃
-CONH ₂	H	H	CH ₃
-CONH-tBu	H	H	COOH
-CONH-tBu	H	H	CONH ₂
Cl	3-Cl	H	COOH
Cl	3-Cl	H	CONH ₂
Cl	3-Cl	H	COOCH ₃
-SO ₂ NH-tBu	H	H	COOH
-SO ₂ NH ₂	H	H	COOH
-SO ₂ NH-tBu	H	H	CONH ₂
-SO ₂ NH ₂	H	H	CONH ₂
OtBu	H	H	CH ₃
OtBu	H	H	COOH


R ⁶	R ⁷	R ²	R ¹
OtBu	H	H	CONH ₂
	H	H	CH ₃
	H	H	COOH
	H	H	CONH ₂
OCH ₂ CF ₃	H	H	CH ₃
OCH ₂ CF ₃	H	H	COOH
OCH ₂ CF ₃	H	H	CONH ₂
CHO	H	H	CONH ₂
H	3-CF ₃	H	CONH ₂
H	4-CF ₃	H	CONH ₂
H	3-F	H	CONH ₂
H	4-Cl	H	CONH ₂
H	4-F	H	CONH ₂
	H	H	CONH ₂
OCH ₃	3-OCH ₃	H	CONH ₂
OCH ₃	5-Cl	H	CONH ₂
CH ₃	H	H	CONH ₂
CH ₃	3-F	H	CONH ₂
	H	H	CONH ₂
H	4-(CH ₂ OH)	H	CONH ₂










R ⁶	R ⁷	R ²	R ¹
H	3-Cl	H	CONH ₂
H	3-OEt	H	CONH ₂
H	4-OEt	H	CONH ₂
F	H	H	CONH ₂
CH ₃	6-CH ₃	H	CONH ₂
H	4-tBu	H	CONH ₂
H	4-OCF ₃	H	CONH ₂
H	4-COCH ₃	H	CONH ₂
H	3-COCH ₃	H	CONH ₂
H	3-(CH ₂ OH)	H	CONH ₂
H	4-CN	H	CONH ₂
H	3-OCF ₃	H	CONH ₂
F	4-F	H	CONH ₂
H	H	H	CONH ₂
OCF ₃	4-N(Me)SO ₂ Me	H	CH ₃
OCF ₃	4-N(Me)SO ₂ Me	H	CONH ₂
OCF ₃	4-NHCO-tBu	H	CH ₃
OCF ₃	4-NHCO-tBu	H	COOH
OCF ₃	4-NHCO-tBu	H	CONH ₂
OCF ₃	H	H	

R^6	R^7	R^2	R^1
OCF_3	H	H	
OCF_3	H	H	
OCF_3	H	H	
OCF_3	H	H	$-CH_2CONH_2$
OCF_3	H	H	$-CH_2CN$
OCF_3	H	H	$-SO_2NHtBu$
OCF_3	H	H	$-SO_2NH_2$
OCF_3	H	H	$-SO_2NHMe$
OCF_3	H	H	$-CH_2OH$
OCF_3	H	H	$-CH(Me)OH$
OCF_3	H	H	$-CH_2NHCOCH_3$
OCF_3	H	H	$-CH_2OSO_2NH_2$
OCF_3	H	H	$-NHCH_3$
OCF_3	H	H	$-NH-CH(CH_3)_2$
OCF_3	H	H	

or a pharmaceutically acceptable salt thereof.

35. The compound of Claim 1 represented by




A	R ¹
	CONH ₂
	CONH ₂
	CONH ₂
	CONH ₂
	CONH ₂
	CONH ₂
	CONH ₂
	CONH ₂
	CONH ₂

or a pharmaceutically acceptable salt thereof.

5

36. The compound of Claim 1 represented by




R ⁶	R ⁴	R ²	R ¹
OCF ₃	4-F	H	CH ₃
OCF ₃	4-F	H	COOH
OCF ₃	4-F	H	COOCH ₃
OCF ₃	4-F	H	CONH ₂
CF ₃	4-F	H	COOCH ₃
CF ₃	4-F	H	CONH ₂
CF ₃	4-F	H	CH ₃
OCF ₃	2-OCH ₂ Ph	H	CH ₃
OCF ₃	2-OH	H	CH ₃
OCF ₃	4-NHAc	H	CH ₃
OCF ₃	4-NHAc	H	COOCH ₃
OCF ₃	4-NHAc	H	CONH ₂
OCF ₃	2-F	H	CH ₃
OCF ₃	2-F	H	COOCH ₃
OCF ₃	2-F	H	CONH ₂
OCF ₃	4-Br	H	CH ₃
OCF ₃	4-Br	H	COOCH ₃
OCF ₃	4-Br	H	CONH ₂
OCF ₃	4-Br	H	COOH
OCF ₃	4-Ph	H	CH ₃
OCF ₃	4-Ph	H	COOCH ₃
OCF ₃	4-Ph	H	CONH ₂
OCF ₃	4-Cl	H	CH ₃
OCF ₃	4-Cl	H	COOCH ₃
OCF ₃	4-Cl	H	COOH
OCF ₃	4-Cl	H	CONH ₂
OCF ₃	2-Cl	H	CH ₃
OCF ₃	2-Cl	H	COOCH ₃
OCF ₃	2-Cl	H	CONH ₂
OCH ₂ CF ₃	4-F	H	CH ₃
OCH ₂ CF ₃	4-F	H	COOCH ₃

R ⁶	R ⁴	R ²	R ¹
OCH ₂ CF ₃	4-F	H	COOH
OCH ₂ CF ₃	4-F	H	CONH ₂
H	4- OCH ₂ CF ₃	H	CONH ₂
OCF ₃	4-F	CH ₃	CH ₃
OCF ₃	4-F	CH ₃	COOCH ₃
OCF ₃	4-F	CH ₃	CONH ₂
F	4- OCH ₂ CF ₃	H	CONH ₂

or a pharmaceutically acceptable salt thereof.

37. The compound of Claim 1 represented by

5




R ⁶	R ²
CF ₃	CH ₃
CF ₃	COOH
CF ₃	CONH ₂
OCF ₃	CH ₃
OCF ₃	COOH
OCF ₃	CONH ₂

or a pharmaceutically acceptable salt thereof.


10

38. A compound represented by



or a pharmaceutically acceptable salt thereof.


39. The compound of Claim 1 represented by



R ⁶	R ¹
OCF ₃	CH ₃
OCF ₃	COOH
OCF ₃	COOCH ₃
OCF ₃	CONH ₂

or a pharmaceutically acceptable salt thereof.

40. The compound of Claim 1 represented by




R ⁶	R ¹
OCF ₃	CH ₃

OCF ₃	COOH
OCF ₃	CONH ₂
CF ₃	CH ₃
CF ₃	COOH
CF ₃	CONH ₂







or a pharmaceutically acceptable salt thereof.

41. The compound of Claim 1 represented by


5



R ⁶	R ⁴	R ³	R ²	R ¹
OCF ₃	H	H	H	CH ₃
OCF ₃	H	H	H	COOH
OCF ₃	H	H	H	CONH ₂
OCF ₃	H	H	H	COOCH ₃
CF ₃	H	H	H	COOH
CF ₃	H	H	H	CONH ₂
Cl	H	H	H	CONH ₂
OCF ₃	H	H	H	CONHC(CH ₃) ₂ CONH ₂
OCF ₃	H	H	H	COCH ₃
OCF ₃	H	H	H	CH(OH)CH ₃
OCF ₃	H	H	H	COCF ₃



R^6	R^4	R^3	R^2	R^1
OCF ₃	H	H	H	CH(OH)CF ₃
OCF ₃	H	H	H	SOCH ₃
OCF ₃	H	H	H	SO ₂ CH ₃
OCF ₃	H	H	H	NHSO ₂ CH ₃
OCF ₃	H	H	CH ₃	NHSO ₂ CH ₃
OCF ₃	H	H	H	NHCO ₂ CH ₃
OCF ₃	H	H	H	NHCOCH ₃
OCF ₃	H	H	H	NHCONH ₂
OCF ₃	H	H	H	NHSO ₂ NH ₂
OCF ₃	H	H	H	N(CH ₃)CONH ₂
OCF ₃	H	H	CH ₃	N(CH ₃)CONH ₂
OCF ₃	H	H	N(CH ₃)CONH ₂	CH ₃
OCF ₃	H	H	H	
OCF ₃	H	H	H	
OCF ₃	H	H	H	
OCF ₃	H	H	H	
OCF ₃	H	H	H	
OCF ₃	H	H	H	
OCF ₃	H	H	H	-CH ₂ CH ₂ CONH ₂

R ⁶	R ⁴	R ³	R ²	R ¹
OCF ₃	H	H	H	-CH ₂ CONH ₂
OCF ₃	H	H	H	-CH ₂ CN
OCF ₃	H	H	H	-SO ₂ NH-tBu
OCF ₃	H	H	H	-SO ₂ NH ₂
OCF ₃	H	H	H	-SO ₂ NHMe
OCF ₃	H	H	H	-CH ₂ OH
OCF ₃	H	H	H	-CH(Me)OH
OCF ₃	H	H	H	-CH ₂ NHCOCH ₃
OCF ₃	H	H	H	-CH ₂ OSO ₂ NH ₂
OCF ₃	H	H	H	-NHCH ₃
OCF ₃	H	H	H	-NH-CH(CH ₃) ₂
OCF ₃	H	H	H	NH ₂
OCF ₃	H	H	CH ₃	OCH ₃
OCF ₃	H	H	OCH ₃	CH ₃
OCF ₃	H	H	CH ₃	OH
OCF ₃	H	H	OH	CH ₃
OCF ₃	H	NH ₂	NH ₂	CONH ₂
OCF ₃	F	H	H	CONH ₂
OCF ₃	H	H	CH ₃	OCON(CH ₃) ₂
OCF ₃	H	H	OCON(CH ₃) ₂	CH ₃
OCF ₃	H	H	CONH ₂	OCH ₃

R ⁶	R ⁴	R ³	R ²	R ¹
OCF ₃	H	H	CH ₃	O(CH ₂) ₂ N(CH ₃) ₂
OCF ₃	H	H	O(CH ₂) ₂ N(CH ₃) ₂	CH ₃
OCF ₃	H	H	OCH ₃	CONH ₂
OCF ₃	H	H	CH ₃	NHCH ₃
OCF ₃	H	H	Cl	CH ₃
OCF ₃	H	H	CH ₃	H
OCF ₃	H	H	H	CH ₃
OCF ₃	H	H	CONH ₂	H
OCF ₃	F	H	CONH ₂	H
OCF ₃	H	H	H	SCH ₃
OCF ₃	H	H	H	S(O)CH ₃
OCF ₃	H	H	H	SO ₂ CH ₃
OCF ₃	F	H	H	COOH
OCF ₃	H	H	H	CHO
OCF ₃	H	H	H	COCH ₃
OCF ₃	H	H	H	CN
OCF ₃	H	H	H	H
OCF ₃	H	H	H	
OCF ₃	H	H	H	CH(OH)CF ₃
OCF ₃	H	H	CH(OH)CF ₃	H
OCF ₃	H	H	CONH ₂	OH


R ⁶	R ⁴	R ³	R ²	R ¹
OCF ₃	H	H	CH ₃	CONH-tBu
OCF ₃	H	H	H	COCF ₃
OCF ₃	H	H	H	-OCH ₂ SO ₂ NH ₂
OCF ₃	H	H	H	-CH=CHCO ₂ CH ₃
OCF ₃	H	H	H	-CH(NH ₂)CH ₂ CONH ₂
OCF ₃	H	H	CONH ₂	OCH ₃
OCF ₃	H	H	H	-CONHCH(CH ₃)CONH ₂
OCF ₃	H	H	H	-CON(CH ₃) ₂
OCF ₃	H	H	H	-O(CH ₂) ₂ N(CH ₃) ₂
OCF ₃	H	H	H	-CH ₂ NHCOCH ₃
CF ₃	H	H	H	COOCH ₃
OCF ₃	H	H	H	S-COCH ₃
CF ₃	H	H	H	CONH ₂
OPh	H	H	H	CONH ₂
OCF ₃	H	H	H	CONHCH ₃
OCF ₃	H	H	NH ₂	NHCH ₃
OCF ₃	H	H	NH ₂	COOPr
Cl	H	H	H	COOCH ₃
OCF ₃	H	H	NH ₂	CONH ₂
Cl	H	H	H	CONH ₂
OCF ₃	H	H	H	CSNH ₂

R ⁶	R ⁴	R ³	R ²	R ¹
OCF ₃	H	H	CH ₃	CONH ₂
OCF ₃	H	H	OCH ₃	CONH ₂
OCF ₃	H	H	H	NHCOCH ₃
OCF ₃	H	H	H	N(COCH ₃) ₂
OCF ₃	H	H	CH ₃	COOH
OCF ₃	H	H	CONH ₂	CONH ₂
OCF ₃	H	H	CH(CH ₃) ₂	CONH ₂
OCF ₃	H	H	CONH ₂	CH(CH ₃) ₂
OCF ₃	H	H	CH(CH ₃) ₂	CONHC(=NH)NH ₂
OCF ₃	H	H	CH(CH ₃) ₂	CONHOH
OCF ₃	H	H	H	NHCONH ₂
OCF ₃	H	CH ₃	H	CONH ₂
OCF ₃	H	CH ₃	CONH ₂	H
OCF ₃	H	H	H	NHCH ₂ CONH ₂
OCF ₃	H	H	H	NHC(=NH)NH ₂
OCF ₃	H	H	H	C(=NH)NH ₂
CF ₃	H	H	H	COOH
OCF ₃	H	Cl	H	CONH ₂
OCF ₃	H	CH ₃	COOH	H
OCF ₃	H	CH ₃	H	COOH
OCF ₃	H	NH ₂	H	CONH ₂

R ⁶	R ⁴	R ³	R ²	R ¹
OCF ₃	H	NH ₂	H	COOH
OCF ₃	H	Cl	H	COOH
OCF ₃	H	NH ₂	CONH ₂	H
OCF ₃	H	CONH ₂	H	CONH ₂
OCH ₂ CF ₃	H	H	CH ₃	Cl
OCH ₂ CF ₃	H	H	Cl	CH ₃
OCH ₂ CF ₃	H	H	H	CH ₃
OCH ₂ CF ₃	H	H	CH ₃	H
OCH ₂ CF ₃	H	H	H	CONH ₂
OCH ₂ CF ₃	H	H	CONH ₂	H
OCH ₂ CF ₃	H	H	H	H
OCH ₂ CF ₃	H	H	H	COOH
	H	H	H	COOCH ₃
	H	H	H	CONH ₂
OCF ₃	H	H	H	CONHC(CH ₃) ₂ CONH ₂
OCF ₃	H	H	H	CH(OH)CH ₃
OCF ₃	H	H	H	NHSO ₂ NH ₂
OCF ₃	H	H	H	N(CH ₃)CONH ₂
OCF ₃	H	H	CH ₃	N(CH ₃)CONH ₂
OCF ₃	H	H	N(CH ₃)CONH ₂	CH ₃

or a pharmaceutically acceptable salt thereof.


42. The compound of Claim 1 represented by



R ⁶	R ⁷	R ⁴	R ²	R ¹
CF ₃	5-F	H	H	CONH ₂
CF ₃	5-F	H	CONH ₂	H
CF ₃	4-CF ₃	H	H	CONH ₂
OCF ₃	H	F	H	CONH ₂
OCF ₃	H	F	CONH ₂	H
CF ₃	4-CF ₃	H	CONH ₂	H
CF ₃	4-CF ₃	H	H	H
Cl	3-Cl	H	H	COOCH ₃
Cl	4-Cl	H	H	COOCH ₃
Cl	3-Cl	H	H	CONH ₂
Cl	4-Cl	H	H	CONH ₂
Cl	6-Cl	H	H	CONH ₂

or a pharmaceutically acceptable salt thereof.

43. A compound represented by



or a pharmaceutically acceptable salt thereof.

44. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

45. The pharmaceutical composition according to Claim 42, further comprising a second therapeutic agent selected from the group consisting of: i) opiate agonists, ii) opiate antagonists, iii) calcium channel antagonists, iv) 5HT receptor agonists, v) 5HT receptor antagonists, vi) sodium channel antagonists, vii) NMDA receptor agonists, viii) NMDA receptor antagonists, ix) COX-2 selective inhibitors, x) NK1 antagonists, xi) non-steroidal anti-inflammatory drugs, xii) selective serotonin reuptake inhibitors, xiii) selective serotonin and norepinephrine reuptake inhibitors, xiv) tricyclic antidepressant drugs, xv) norepinephrine modulators, xvi) lithium, xvii) valproate, and xviii) neurontin.

46. A method of treatment or prevention of pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

47. A method of treatment of chronic, visceral, inflammatory or neuropathic pain syndromes comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

48. A method of treatment of pain resulting from, or associated with, traumatic nerve injury, nerve compression or entrapment, postherpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, cancer or chemotherapy, comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

49. A method of treatment of chronic lower back pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

50. A method of treatment of phantom limb pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

51. A method of treatment of HIV- and HIV treatment-induced neuropathy, chronic pelvic pain, neuroma pain, complex regional pain syndrome, chronic arthritic pain or related neuralgias comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

52. A method of administering local anesthesia comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

53. A method of treatment of irritable bowel syndrome or Crohns disease comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

54. A method of treatment of epilepsy or partial and generalized tonic seizures comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

55. A method for neuroprotection under ischaemic conditions caused by stroke or neural trauma comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

56. A method of treatment of multiple sclerosis comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically

effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

5 57. A method of treatment of bipolar disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

10 58. A method of treatment of tachy-arrhythmias comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.